3 results about "Hypoxia reoxygenation" patented technology

The application discloses a traditional Chinese medicine composition, a medicine preparation and application thereof, and belongs to the technical field of traditional Chinese medicine compositions. The traditional Chinese medicine composition comprises herba rhizomatosi and herba rhizomatosi, and the mass ratio of the herba rhizomatosi and the herba rhizomatosi is 1:1. The traditional Chinese medicine composition, the medicine preparation and the application thereof are based on the compatibility of the kidney-nourishing and heart-nourishing theory of traditional Chinese medicine, utilize the herba rhizomatosi and the herba rhizomatosi to form a kidney-yang tonifying traditional Chinese medicine pair, and are consistent with the core pathogenesis of MIRI. The corresponding traditional Chinese medicine composition of the traditional Chinese medicine pair can inhibit cell apoptosis, reduce the level of inflammatory factors in cells, relieve calcium ion overload and improve cell survival rate, so as to improve the hypoxia / reoxygenation-induced H9C2 myocardial cell damage state in multiple dimensions. The traditional Chinese medicine composition can activate estrogen receptors to inhibit the expression of related proteins in the endoplasmic reticulum stress signal pathway, and simultaneously regulate the expression of apoptosis-related proteins, thereby laying a foundation for the application of phytoestrogen therapy in the field of cardiovascular diseases and having significant clinical transformation value and market potential.

The application aims to provide an application of a biological agent in treating placental dysfunction, and belongs to the technical field of medicine.The biological agent is composed of siRNA for inhibiting expression of a LOC101929800 gene, a transcript sequence of the LOC101929800 gene is SEQ ID NO.1 in the sequence listing, and a sequence of the siRNA is SEQ ID NO.10 and SEQ ID NO.11 in the sequence listing.The application finds that the siRNA can reverse the decrease of the invasion ability of the trophoblast cells caused by hypoxia-reoxygenation to a certain extent by transfecting the siRNA in the cells under hypoxia-reoxygenation, and therefore the siRNA can be used for preparing the biological agent for treating placental injury.

This invention provides a gas control device for experiments involving hypoxia / reoxygenation of cardiomyocytes. [Solution] The system comprises three parallel intake branch pipes 4 integrating a precision needle-type throttling structure, a multi-stage mixing chamber 6 connected thereto, a gradient switching mechanism, and a pressure balancing device. The gradient switching mechanism includes a fixed plate 9 and a movable plate, with multiple throttling holes of different diameters in the fixed plate and gas passage holes in the movable plate, allowing the airflow cross-sectional area to be switched in steps by rotating the movable plate. This solves the problem of pressure fluctuations during gas environment switching interfering with cellular responses, achieves highly accurate and smooth switching between hypoxia and reoxygenation, eliminates instantaneous pressure pulses, provides an accurate and uniform mixed gas for the hypoxia / reoxygenation (H / R) model, and is applicable to molecular mechanism studies of myocardial ischemia-reperfusion injury (MIRI).